Yep from what I read you could assume that loans and obligations have blown out from about $US25m to somewhere around $38m.
I'm assuming Kedrion didn't want to cough up any more cash hence the delay in negotiations...so one could assume the deal with Kedrion is off.
The deal with Octapharma seems a bit strange with a put / call option which allows LFE to exercise at any time and Octapharama only after a period 13 months. What's the point except that LFE might think they can generate some cash flow in that period. If they can't then it seems Octapharma will cover the cost less interest in the exercise price ?
Weird but seems to favour both parties in that LFE gets a free run so to speak and Octapharama have locked in a cheap price for a growing business.
LFE Price at posting:
0.0¢ Sentiment: None Disclosure: Held
